Farmácia/Notícias da Indústria
Estudo randomizado | Patiromer para tratamento de hiperpotassemia na insuficiência cardíaca com fração de ejeção reduzida.
5 Ago, 2022 | 16:27h
Comentário no Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.
4 Ago, 2022 | 14:09hSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022
Revisão | Tratamento da insuficiência cardíaca em pacientes com doença renal crônica.
2 Ago, 2022 | 13:02hManagement of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review
M-A | Risco tromboembólico cardiovascular e venoso com inibidores da Janus quinase nas doenças inflamatórias imunomediadas.
2 Ago, 2022 | 12:56h
Grande estudo observacional sugere que antipsicóticos injetáveis de ação longa estão associados a desfechos melhores do que antipsicóticos orais em pessoas com esquizofrenia.
1 Ago, 2022 | 15:12hComentário convidado: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Conteúdos relacionados:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link para o resumo – $ para o texto completo)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Comentário no Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Estudo randomizado | Teste farmacogenômico para interações medicamento-genes fornece pouco benefício à remissão de sintomas no transtorno depressivo maior.
18 Jul, 2022 | 13:04hEffect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress – JAMA (gratuito por tempo limitado)
Comentário: Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder? — The evidence is unclear – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
In this randomized clinical trial, pharmacogenomic testing for drug-gene interactions in major depressive disorder reduced prescription of medications with predicted drug-gene interactions but had small and nonpersistent effects on symptom remission. https://t.co/Z2OIK3h1Bo pic.twitter.com/8eKSipfBFN
— JAMA (@JAMA_current) July 12, 2022
FDA autoriza o uso emergencial da vacina Novavax contra COVID-19.
18 Jul, 2022 | 13:01hComentários:
FDA authorizes Novavax Covid vaccine, in hopes the traditional shot will convince holdouts – STAT
US regulators OK new COVID-19 shot option from Novavax – Associated Press
Estudo de coorte de abrangência nacional | Segurança dos esquemas de vacinação primária heteróloga e reforços com vacinas ChAdOx1-S e BNT162b2 ou mRNA-1273.
18 Jul, 2022 | 12:54h
M-A de estudos randomizados | Acetato de megestrol não é benéfico para a anorexia/caquexia relacionada ao câncer.
18 Jul, 2022 | 12:53h
Diretrizes de enfermagem da EBMT sobre a terapia CAR-T | Estrutura para o cuidado do paciente e tratamento das toxicidades comuns.
18 Jul, 2022 | 12:50h